First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
4Large contract wins or losses with top 20 pharma clients (top 10 clients represent ~30% of revenue; single contract can be $100M+ annually)
5Margin expansion trajectory in R&D Solutions (labor utilization rates, offshore delivery mix, automation of trial monitoring)
6Technology & Analytics Solutions (~50% of revenue): Real-world data products, commercial analytics, consulting services to pharma/biotech for market access, pricing, and launch optimization
7R&D Solutions (~50% of revenue): Full-service clinical trial management (Phase I-IV), site networks, patient recruitment, regulatory consulting, and decentralized trial technologies
8Contract Sales Organization services: Field sales forces deployed on behalf of pharma clients for product launches and promotional activities
value-growth hybrid - The stock attracts investors seeking exposure to secular healthcare outsourcing trends (5-7% organic growth)…
Rising rates create moderate headwinds through two channels: (1) Higher financing costs on $9.5B gross debt (mix of fixed/floating…
Watch on earnings: Global pharmaceutical R&D spending growth rate (industry reports from EvaluatePharma, IQVIA Institute; target: 3-6% annual growth), Biotech venture capital funding and IPO proceeds (PitchBook data; leading indicator for small/mid-cap trial starts with 6-12 month lag), FDA and EMA new drug approvals (proxy for pipeline health and future commercial analytics demand; 50-60 annual approvals typical).
One Sentence Summary:
IQVIA: the story is balanced — contracted backlog growth and book-to-bill ratio (indicates future revenue visibility; backlog typically $25b+ representing 18+ months.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.